Human Genetics Society of Australasia Position Statement: Genetic Testing and Personal Insurance Products in Australia.

Australia Genetic testing discrimination genomics insurance regulation

Journal

Twin research and human genetics : the official journal of the International Society for Twin Studies
ISSN: 1832-4274
Titre abrégé: Twin Res Hum Genet
Pays: England
ID NLM: 101244624

Informations de publication

Date de publication:
04 2023
Historique:
medline: 21 7 2023
pubmed: 25 5 2023
entrez: 25 5 2023
Statut: ppublish

Résumé

The expansion of genetic and genomic testing in clinical practice and research, and the growing market for direct-to-consumer genomic testing has led to increased awareness about the impact of this form of testing on insurance. Genetic or genomic information can be requested by providers of mutually rated insurance products, who may then use it when setting premiums or determining eligibility for cover under a particular product. Australian insurers are subject to relevant legislation and an industry led standard that was updated in 2019 to introduce a moratorium on the use of genetic test results in life insurance underwriting for policies <AU$500K. The Human Genetics Society of Australasia has updated its position statement on genetic testing and life insurance to account for these changes and to increase the scope of the statement to include a wider range of personally-rated insurance products, such as life, critical care, and income protection products. Recommendations include that: providers of professional education involving genetics should include ethical, legal, and social aspects of insurance discrimination in their curricula; the Australian Government take a more active role in regulating use of genetic information in personal insurance; that information obtained in the course of a research project be excluded; insurers seek expert advice when making underwriting decisions regarding genetic testing; and engagement between the insurance industry, regulators, and the genetics profession be improved.

Identifiants

pubmed: 37226735
pii: S1832427423000117
doi: 10.1017/thg.2023.11
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

184-187

Auteurs

Aideen M McInerney-Leo (AM)

Frazer Institute, The University of Queensland, Dermatology Research Centre, Brisbane, Queensland, Australia.

Samantha Ayres (S)

Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia.

Jackie Boyle (J)

Genetics of Learning Disability Service, Waratah, New South Wales, Australia.

Chris Jacobs (C)

Graduate School of Health, University of Technology Sydney, NSW, Australia.

Ainsley J Newson (AJ)

The University of Sydney, Faculty of Medicine and Health, Sydney School of Public Health, Sydney Health Ethics, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH